Atopic dermatitis is one of the most common chronic diseases of childhood and closely related to other clinical manifestations of allergy. The incidence is high and still increasing. The genetic contribution to disease development is substantial and complex. Only recently genetic research has begun to focus on this phenotype, and specific susceptibility genes remain to be found. To identify candidate regions holding genes for atopic dermatitis we performed a genome-scan in Danish affected sib-pair families containing sib-pairs matching a phenotype definition of both clinical atopic dermatitis and confirmed specific allergy. The scan was undertaken using 446 microsatellite markers and non-parametric linkage results were obtained from the MAPMAKER/SIBS computer program. We found evidence of linkage to three candidate regions in chromosomes 3p (MLS = 2.14), 4p (MLS = 2.00) and 18q (MLS = 2.25), one of which has not been reported previously. Eight additional regions showed weaker but positive results. 

Key words: allergy; candidate; gene; genetics; region.

(Accepted April 12, 2004.)

Acta Derm Venereol 2004; 84: 346–352.

A. Haagerup, Institute of Human Genetics, Bartholin Building, Aarhus University, DK-8000 Aarhus C, Denmark. E-mail: ah@humgen.au.dk

Atopic dermatitis (AD) (MIM 603165) is a chronic relapsing dermatitis associated with high levels of IgE and often co-existing with asthma and/or rhinitis. Type I allergies develop in about one-third of patients with AD and most frequently among those who later also develop asthma or rhinitis (1). In 90% of these patients the disease presents before 4 years of age (2).

The incidence of AD during childhood has increased 5–10-fold over the past four decades to 15–20% for children born in 1980–1990 (3, 4). The exact reasons for this worrying development of the disease frequency remain to be found.

AD is a complex genetic disorder, since the disease is thought to develop in genetically predisposed individuals due to specific environmental factors. Family and twin studies estimate the genetic predisposition of AD to be considerable (5, 6) and a complex pathogenesis with polygenic inheritance is expected. As for many diseases with complex genetics, it is generally believed that the major reasons for the increasing incidence must be found in our environment, because the genetic pool has not changed overall during the relatively limited period of time. However, molecular genetics may offer the key to better understanding of the pathogenesis of AD and, thus, in time will provide a platform from which our insight into the environmental risk factors can further expand. Therefore, identification of AD susceptibility genes is likely to facilitate future understanding, prevention, diagnosis and treatment of AD.

The AD phenotype has previously been genetically evaluated by linkage and association (see for example Refs 7–9). Three genome-scans have reported on a small number of candidate loci for AD (10–12).

Attempts to confirm atopy candidate regions unfortunately often produce conflicting results. This might be explained by variations in study design, diagnostic criteria and statistical methods and by genetic heterogeneity in the different populations studied (13). We believe that the use of a narrow allergy phenotype definition, which combines both strict clinical diagnosis and evidence of specific sensitization, defines a more aetiological homogeneous group of patients and thereby increases the chance of detecting susceptibility genes. We previously introduced and employed this strategy (14–16). To further dissect the genetics of AD, we sampled Danish affected sib-pair families by a narrow phenotype definition and carried out a genome-scan using 446 highly informative microsatellite markers. Data were analysed by non-parametric multipoint linkage analysis and revealed evidence of linkage to 11 candidate regions. Six of the regions emphasized by our study support earlier linkage reports of asthma, atopy or rhinitis candidate regions.

MATERIALS AND METHODS

Patients and participants

A total of 424 individuals from 100 Danish nuclear families selected for clinical atopy were enrolled in the Danish allergy project ITA (Inheritance of Type I Allergy). The families were recruited from the western part of Denmark through one adult and four paediatric outpatient allergy clinics in Aarhus, Herning, Viborg and Aalborg. All participants (200 parents and 224 children) were clinically examined and questionnaire-tested by one doctor. They had blood drawn...
for DNA analysis and serum measurement of total IgE and specific IgE, RAST, to 11 common allergens. Among the offspring the mean age was 10.8 years and the male/female sex ratio was 1.2; equivalent to random distribution ($p = 0.35$). The ITA project was carried out in accordance with the Helsinki declaration and approved by the Danish scientific ethical committee system. All participants and/or their parents gave informed consent.

**Phenotype definition**

In the ITA project we have chosen to evaluate five distinct phenotypes of type I (immediate type) allergy: atopy, allergic asthma, allergic rhinitis, AD and increased total IgE. All phenotypes include, in addition to the specific clinical phenotype character, increased specific IgE measurements against at least one of the tested allergens, i.e. $\text{RAST} \geq 1+$. The results of the genome-scans for allergic rhinitis (15) and allergic asthma, atopy and increased total IgE (16) were reported elsewhere.

In the present study we report the results of the genome-scan for AD defined by the phenotype: clinical AD and increased specific IgE against at least one of the tested allergens ($\text{RAST} \geq 1+$).

This phenotype is equivalent to the IgE-associated atopic eczema/dermatitis syndrome, AEDS, proposed in EAACI recommendations (17). Families holding at least two full siblings with the above outlined phenotype were selected. The specific IgE measurements (CAP RAST FEIA, Pharmacia, Uppsala, Sweden) were increased when $\geq 0.35 \text{kUA/l} (\geq \text{class I})$ and determined for 11 allergens: grass, birch, mugwort, olive, Pariaetaria, cat, dog, horse, mite (D. pteronyssinus and D. farinae) and Cladosporium herbarum. AD was diagnosed according to the Hanifin & Rajka criteria (18) and determined for 11 families: Urban allergy, start allergy, atopy and increased total IgE. All phenotypes of type I (immediate type) allergy: atopy, allergic asthma, allergic rhinitis, AD and increased total IgE. All phenotypes include, in addition to the specific clinical phenotype character, increased specific IgE measurements against at least one of the tested allergens, i.e. $\text{RAST} \geq 1+$.

This phenotype is equivalent to the IgE-associated atopic eczema/dermatitis syndrome, AEDS, proposed in EAACI recommendations (17). Families holding at least two full siblings with the above outlined phenotype were selected. The specific IgE measurements (CAP RAST FEIA, Pharmacia, Uppsala, Sweden) were increased when $\geq 0.35 \text{kUA/l} (\geq \text{class I})$ and determined for 11 allergens: grass, birch, mugwort, olive, Pariaetaria, cat, dog, horse, mite (D. pteronyssinus and D. farinae) and Cladosporium herbarum. AD was diagnosed according to the Hanifin & Rajka criteria (18) and determined for 11 families: Urban allergy, start allergy, atopy and increased total IgE. All phenotypes of type I (immediate type) allergy: atopy, allergic asthma, allergic rhinitis, AD and increased total IgE. All phenotypes include, in addition to the specific clinical phenotype character, increased specific IgE measurements against at least one of the tested allergens, i.e. $\text{RAST} \geq 1+$.

The relatively small sample of sib-pair families available to this study limited the application of further statistical analysis. Therefore, evaluation of clinical subgroups or parent of origin effects were not pursued, as so not to lose statistical power. However, in the future such calculations may become relevant for the analysis of identified specific susceptibility gene variants and their implication in disease severity. This most likely will require a larger sample.

**RESULTS**

We found linkage of AD to three regions defined by MLS $\geq 2$. The regions were 3p26–3p24 (MLS = 2.14), 4p15–4p14 (MLS = 2.00) and 18q11–18q12 (MLS = 2.25). Another eight regions (5q21–5q23, 6q13–6q14, 9p23–9p22, 12q23, 18p11, 22q11–22q12, Xp22–Xp21 and Xp11) showed evidence of linkage characterized by MLS from 1–2. Results of the multipoint linkage analysis for the nine chromosomes with MLS $>1$ are shown as plots by chromosome (Fig. 1). Specific data from the 11 regions with MLS $>1$ are given (Table II).

The reported results were obtained by computing data using the conservative independent sib-pairs facility from the MAPMAKER/SIBS program. From simulations it was estimated that the likelihood of finding three or more loci with MLS $\geq 2$ in one genome-scan by chance was $p = 0.08$. Consequently the probability that at least one of the three loci harbours an AD susceptibility gene is 92%.

Both NPL and Zlr statistics approximately follow the standard normal distribution when the sample is...
sufficient. However, when the IBD information provided by the data is incomplete (missing data, low heterozygosity or sparse markers), the NPL approach will become conservative when compared to the Zlr approach, and in that case different conclusions can be expected. Our results showed that both the NPL and the Zlr statistics captured the three highest peaks found by the MLS approach. The NPL scores were 3.13 ($p = 0.0009$), 2.84 ($p = 0.0023$), 2.49 ($p = 0.006$) and the Zlr results were 3.08 ($p = 0.001$), 2.24 ($p = 0.0126$), 2.73 ($p = 0.004$) for the peaks found on chromosomes 3, 4 and 18, respectively. Thus, these results indicate that, although our sample is limited, the data are sufficiently informative.
Three general atopy candidate genes were tested for linkage. For the TNF-β (chromosome 6) and FcεR1β (chromosome 11) genes the MLSs were 0.23 and 0.19, respectively. The IL4 receptor (IL4R) alpha-subunit region between marker D16D769 and D16S409 on chromosome 16 gave maximum MLS of 0.03.

Information content reflects both marker density and marker heterozygosity and is useful in predicting the marker map quality. The information content was high throughout the genome and the mean value in the 11 appointed regions (Table II) was 0.85 (range 0.61–0.97).

DISCUSSION

Over the past decade intensive research into the complex genetics of allergy has generated numerous reports of linkage and association. The genetic model for allergic disease still remains to be determined but a combination of general allergy genes and organ-specific genes has been suggested (24). In the present study we evaluated the clinical phenotype AD combined with documented type I allergy, RAST ≥1+. The narrow phenotype definition was used in an attempt to decrease the genetic heterogeneity and thereby increase the power of the study (24). We obtained the highest LOD scores in three regions on chromosomes 3p, 4p and 18q (Table II).

The region on 3p26–3p24 was (Fig. 1) identified in our study by the flanking markers D3S3594 and D3S3038. Previously suggestive linkage of AD to marker D3S1768 on chromosome 3p21 has been found (12). For the same marker we did not find linkage (MLS~0.17). The distance between the peak markers of the two studies is approximately 13 cM. Our result may be seen as support for and refinement of the AD candidate region on chromosome 3p.

On chromosome 18q11–18q12 our peak marker D18S877 is located almost 30 cM proximal to the marker D18S851 (MLS=0) that also suggested linkage of AD in the Swedish population (12). These two different observations were both based on evaluation of an AD phenotype of combined clinical symptoms and increased specific IgE.
Thus, of the three identified susceptibility candidate regions for AD the locus on chromosome 4p is new, whereas our finding on 3p and 18q provides support for previous results in these regions. When observing the allele sharing patterns in the three regions the genetic contributions on 3p and 4p were most consistent with recessive inheritance, whereas the pattern in the 18q region clearly was compatible with dominant inheritance.

We have previously reported evidence in favour of linkage of atopy to the locus on chromosome Xp11 (16). The same locus has shown suggestive linkage by a single-point analysis for an extreme AD phenotype (12). Our present study confirms both the locus as a strong candidate locus for AD as well as our previous finding in the region. The three studies all identified DXS6800 as peak marker in the region, which also harbours the gene for the Wiskott-Aldrich syndrome (WAS) characterized by eczema, thrombocytopenia, proneness to infection and bloody diarrhoea. The WAS gene has been suggested as an AD candidate gene (25).

Our results in another five of the identified regions, although insignificant by themselves, supported earlier reports evaluating asthma, rhinitis, atopy or other allergy-related phenotypes; i.e. chromosomes 3p (26), 4p (15, 16), 5q (15, 16, 26–30), 9p (31) and 12q (32–34). Four new regions (6q, 18p, 22q and Xp22–Xp21) showed weak but positive results, MLS 1.04–1.69. Interestingly a case of late-onset AD in a patient with complex glycerol kinase deficiency caused by a micro-deletion on Xp21 was recently reported (35). On the basis of this report and our result on Xp22–Xp21 we suggest the gene for glycerol kinase or a closely linked gene as a candidate gene for AD.

Genetic studies evaluating the AD phenotype have investigated the regions 5q31 (IL4), 6p21 (TNF-β), 11q13 (FceR1β), 12q, 13q, 14q11 (MCC), 16p (IL4Rα), 17q11 (RANTES). Our study revealed some support for the regions 5q and 12q as described above. No evidence of linkage was found to the atopy candidate genes TNF-β (MLS = 0.23) and FceR1β (MLS = 0.19) or to the IL4R region (MLS = 0.03).

Our study neither replicated nor excluded the findings in two previous AD genome-scans (10, 11), just as they did not confirm or exclude each other. Overall the three studies varied in sample and marker panel sizes, and they applied different statistics and phenotype definition to different populations. We used

| Cytogenetic position | Marker map position (cM) | Marker | Infoa | MLSb |
|----------------------|--------------------------|--------|-------|------|
| 3p26–3p24            | 17.90                    | D3S3594| 0.85  | 1.51 |
|                      | 25.37                    |        | 0.61  |      |
|                      | 30.35                    | D3S3038| 0.80  | 1.93 |
| 4p15–4p14            | 29.81                    | D4S2397| 0.90  | 1.29 |
|                      | 33.04                    | D4S2408| 0.95  | 2.00 |
|                      | 37.60                    | D4S2629| 0.96  | 1.26 |
| 5q21–5q23            | 115.62                   |        | 0.83  | 1.16 |
|                      | 117.51                   | D5S1466| 0.92  | 1.14 |
| 6q13–6q14            | 86.80                    | D6S1043| 0.95  | 1.33 |
|                      | 88.70                    | D6S1056| 0.93  | 1.07 |
| 9p23–9p22            | 24.20                    | D9S269 | 0.87  | 1.54 |
| 12q23                | 106.60                   |        | 0.72  | 1.42 |
|                      | 108.60                   | D12S353| 0.81  | 1.28 |
| 18p11                | 28.10                    | D18S843| 0.78  | 1.04 |
| 18q11–18q12          | 54.50                    | D18S877| 0.91  |      |
| 22q11–22q12          | 10.40                    | D22S446| 0.74  | 1.26 |
|                      | 13.96                    |        | 0.64  | 1.53 |
|                      | 19.30                    | D22S310| 0.97  | 1.04 |
|                      | 22.90                    |        | 0.76  | 1.21 |
| Xp22–Xp21            | 0.00                     | DXS6807| 0.86  | 1.54 |
|                      | 3.50                     | DXS6800| 0.95  | 1.50 |
| Xp11                 | 39.20                    | DXS7132| 0.85  | 1.22 |

Regions presenting MLS > 1 are listed both by cytogenetic and genetic map positions.

*a*Information content (Info) is given for all suggestive positions.

*b*Increased maximum likelihood IBD score (MLS) scores obtained between markers are included to place a potential candidate gene in relation to a close marker. MLS > 2 and relating markers are shown in bold.
a higher marker density in a more limited sample size and criteria for the clinical diagnosis similar to Lee et al. (10), and we strengthened our phenotype definition to gain power. In conclusion, we sampled a clinically thoroughly described set of allergy sib-pair families and conducted a comprehensive genome-scan in a search for AD candidate genes. A narrow phenotype definition, 446 highly informative markers and conservative statistical analysis were used. Three AD candidate regions were identified by LOD scores > 2. Moreover, we found evidence supporting an additional eight regions. The region on chromosome 4p was a new locus for AD, and the three regions, 3p, 18q and Xp11, represented confirmation of previously reported AD loci. Also, five of the 11 regions were confirmatory to reports suggesting linkage of other allergy phenotypes. Our study supported the theory of a heterogeneous inheritance of AD and contributed to the few known AD candidate loci.

ACKNOWLEDGEMENTS

We thank patients and their families for participating in the ITA project. The enthusiastic co-operation by the staff of the five outpatient allergy clinics in Aalborg, Viborg, Herning and Aarhus during recruitment of the allergy families is highly appreciated. The project was funded by the Ville Heises Fund; the Faculty of Health Sciences, the University of Aarhus; Horslev Fund; the Danish Lung Association; the Danish Allergy Research Centre; the Danish Asthma-Allergy Association, the Mimi and Victor Larsen’s Fund and ALK Abello Denmark.

REFERENCES

1. Rudzki E, Litewska D. RAST and PRIST in children with atopic dermatitis. Dermatologica 1990; 180: 82 – 85.
2. Olesen AB, Ellingsen AR, Larsen FS, Larsen PO, Veien NK, Thesstrup-Pedersen K. Atopic dermatitis may be linked to whether a child is first- or second-born and/or the age of the mother. Acta Derm Venereol 1996; 76: 457 – 460.
3. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34: 760 – 764.
4. Olesen AB, Ellingsen AR, Olesen H, Juul S, Thesstrup-Pedersen K. Atopic dermatitis and birth factors: historical follow up by record linkage [see comments]. BMJ 1997; 314: 1003 – 1008.
5. Marsh DG, Meyers DA, Bias WB. The epidemiology and genetics of atopic allergy. N Engl J Med 1981; 305: 1551 – 1559.
6. Schultz Larsen F, Hanifin JM. Secular change in the occurrence of atopic dermatitis. Acta Derm Venereol Suppl 1992; 176: 7 – 12.
7. Coleman R, Trembath RC, Harper JI. Chromosome 11q13 and atopy underlying atopic eczema. Lancet 1993; 341: 1121 – 1122.
8. Mao XQ, Shirakawa T, Yoshikawa T, Yoshikawa K, Kawai M, Sasaki S, et al. Association between genetic variants of mast-cell chymase and eczema [see comments] [published erratum appears in Lancet 1997; 349 (9044): 64]. Lancet 1996; 348: 581 – 583.
9. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000; 164: 1612 – 1616.
10. Lee YA, Wahn U, Kehrt R, Tarani L, Businco L, Gustafsson D, et al. A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. Nat Genet 2000; 26: 470 – 473.
11. Cookson WO, Ubhi B, Lawrence R, Abecasis GR, Walley AJ, Cox HE, et al. Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. Nat Genet 2001; 27: 372 – 373.
12. Bradley M, Soderhall C, Luthman H, Wahlgren CF, Kockum I, Nordenskjold M. Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. Hum Mol Genet 2002; 11: 1539 – 1548.
13. Coleman R, Trembath RC, Harper JI. Genetic studies of atopy and atopic dermatitis. Br J Dermatol 1997; 136: 1 – 5.
14. Haagerup A, Bjerke T, Schiotz PO, Dahl R, Binderup HG, Kruse TA. No linkage and association of atopy to chromosome 16 including the interleukin-4 receptor gene. Allergy 2001; 56: 775 – 779.
15. Haagerup A, Bjerke T, Schiotz PO, Binderup HG, Dahl R, Kruse TA. Allergic rhinitis – a total genome-scan for susceptibility genes suggests a locus on chromosome 4q24 – q27. Eur J Hum Genet 2001; 9: 945 – 952.
16. Haagerup A, Bjerke T, Schiotz PO, Binderup HG, Dahl R, Kruse TA. Asthma and atopy – a total genome scan for susceptibility genes. Allergy 2002; 57: 680 – 686.
17. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haasthela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813 – 824.
18. Hanifin YM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl 1980; 92: 44 – 47.
19. Risch N. Linkage strategies for genetically complex traits. III. The effect of marker polymorphism on analysis of affected relative pairs [published erratum appears in Am J Hum Genet 1992; 51: 673 – 675] [see comments]. Am J Hum Genet 1990; 46: 242 – 253.
20. Kruglyak L, Lander ES. Complete multipoint sib-pair analysis of quantitative and qualitative traits [see comments]. Am J Hum Genet 1995; 57: 439 – 454.
21. Kruglyak L, Daly MJ, Reeve-Daly MP, Lander ES. Parametric and nonparametric linkage analysis: a unified multipoint approach. Am J Hum Genet 1996; 58: 1347 – 1363.
22. Kong A, Cox NJ. Allele-sharing models: LOD scores and accurate linkage tests. Am J Hum Genet 1997; 61: 1179 – 1188.
23. Gudbjartsson DF, Jonasson K, Frigge ML, Kong A. Allegro, a new computer program for multipoint linkage analysis. Nat Genet 2000; 25: 12 – 13.
24. Wiltshire S, Bhattacharyya S, Faux JA, Leaves NJ, Daniels SE, Moffatt MF, et al. A genome scan for loci influencing total serum immunoglobulin levels: possible linkage of IgA to the chromosome 13 atopy locus. Hum Mol Genet 1998; 7: 27 – 31.
25. Bradley M, Soderhall C, Wahlgren CF, Luthman H, Nordenskjold M, Kockum I. The Wiskott-Aldrich
syndrome gene as a candidate gene for atopic dermatitis. Acta Derm Venereol 2001; 81: 340–342.

26. Ober C, Cox NJ, Abney M, Di Rienzo A, Lander ES, Changyaleket B, et al. Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the Genetics of Asthma. Hum Mol Genet 1998; 7: 1393–1398.

27. Marsh DG, Neely JD, Breazeale DR, Ghosh B, Freidhoff LR, Ehrlich-Kautzky E, et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994; 264: 1152–1156.

28. Meyers DA, Postma DS, Panhuysen CI, Xu J, Amelung PJ, Levitt RC, et al. Evidence for a locus regulating total serum IgE levels mapping to chromosome 5. Genomics 1994; 23: 464–470.

29. Postma DS, Bleecker ER, Amelung PJ, Holroyd KJ, Xu J, Panhuysen CI, et al. Genetic susceptibility to asthma – bronchial hyperresponsiveness co-inherited with a major gene for atopy. N Engl J Med 1995; 333: 894–900.

30. CSGA. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA). Nat Genet 1997; 15: 389–392.

31. Wjst M, Fischer G, Immervoll T, Jung M, Saar K, Rueschendorf F, et al. A genome-wide search for linkage to asthma. German Asthma Genetics Group. Genomics 1999; 58: 1–8.

32. Barnes KC, Neely JD, Duffy DL, Freidhoff LR, Breazeale DR, Schou C, et al. Linkage of asthma and total serum IgE concentration to markers on chromosome 12q: evidence from Afro-Caribbean and Caucasian populations. Genomics 1996; 37: 41–50.

33. Nickel R, Wahn U, Hizawa N, Maestri N, Duffy DL, Barnes KC, et al. Evidence for linkage of chromosome 12q15–q24.1 markers to high total serum IgE concentrations in children of the German Multicenter Allergy Study. Genomics 1997; 46: 159–162.

34. Wilkinson J, Grimley S, Collins A, Thomas NS, Holgate ST, Morton N. Linkage of asthma to markers on chromosome 12 in a sample of 240 families using quantitative phenotype scores. Genomics 1998; 53: 251–259.

35. Sueyoshi F, Abe Y, Katayama I, Baba T, Yoshimoto M. Late-onset atopic dermatitis in complex glycerol kinase deficiency with chromosome Xp21 region deletion: is there a pathogenic relationship? Dermatology 1999; 198: 98–99.